GlassScriptPhysician profile
David J Bene
NPI 1598879462
$5,491.56
in general payments reported to CMS, 2019-2025
21 companies · $352 in 2025
The $352 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $187 · 2021: $107 · 2022: $2,418 · 2023: $125 · 2024: $2,063 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,680 · Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,680.04 |
| Food and Beverage | $859.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,820.22 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $1,764.16 | 2024 | Iolmaster 700, Veracity Surgical, Visumax |
| Notal Vision, INC. | $327.01 | 2022 | |
| Allergan, INC. | $312.10 | 2019-2021 | |
| Abbvie INC. | $234.25 | 2022-2025 | Ozurdex |
| Johnson & Johnson Surgical Vision, INC. | $163.24 | 2022 | |
| Bausch & Lomb Americas INC. | $152.65 | 2022-2025 | Xiidra, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $112.99 | 2019-2025 | Cequa |
| Amgen INC. | $99.19 | 2024-2025 | Tepezza |
| Dompe US, INC. | $64.40 | 2024 | Oxervate |
| Alcon Vision LLC | $62.20 | 2022-2025 | Hydrus Microstent, Rocklatan |
| Aerie Pharmaceuticals, INC. | $59.55 | 2019-2021 | |
| Sight Sciences, INC. | $55.17 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.94 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $44.29 | 2024-2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.65 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $35.82 | 2021 | |
| Rayner Intraocular Lenses Limited | $31.74 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Merz Pharmaceuticals, LLC | $28.01 | 2023 | Xeomin |
| Eyevance Pharmaceuticals LLC | $26.74 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.